​
​

BioXcel Therapeutics (BTAI) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

BioXcel Therapeutics Revenue Highlights

Latest Revenue (Y)

$1.38M

Latest Revenue (Q)

$1.10M

BioXcel Therapeutics Revenue by Period

BioXcel Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$1.38M268.00%
2022-12-31$375.00K100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31-100.00%
2016-12-31--

BioXcel Therapeutics generated $1.38M in revenue during NA 2023, up 268.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

BioXcel Therapeutics Revenue by Quarter

DateRevenueChange
2024-06-30$1.10M89.69%
2024-03-31$582.00K54.79%
2023-12-31$376.00K10.26%
2023-09-30$341.00K-25.38%
2023-06-30$457.00K121.84%
2023-03-31$206.00K-13.45%
2022-12-31$238.00K73.72%
2022-09-30$137.00K100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31--100.00%
2020-12-31$0.02100.00%
2020-09-30$0.01100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31-100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2017-03-31--

BioXcel Therapeutics generated $1.10M in revenue during Q2 2024, up 89.69% compared to the previous quarter, and up 535.92% compared to the same period a year ago.

BioXcel Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
EXELExelixis$1.83B$478.06M
AMLXAmylyx Pharmaceuticals$380.79M$416.00K
APLSApellis Pharmaceuticals$366.28M$176.57M
TGTXTG Therapeutics$233.66M$83.88M
MREOMereo BioPharma Group$10.00M-
BTAIBioXcel Therapeutics$1.38M$1.10M
XFORX4 Pharmaceuticals-$560.00K
VKTXViking Therapeutics--
DAWNDay One Biopharmaceuticals-$20.07M
ABOSAcumen Pharmaceuticals--
INZYInozyme Pharma--
ELEVElevation Oncology--
MDGLMadrigal Pharmaceuticals-$62.17M
TERNTerns Pharmaceuticals--
HEPAHepion Pharmaceuticals--
EFTReFFECTOR Therapeutics--

BTAI Revenue FAQ

What is BioXcel Therapeutics’s yearly revenue?

BioXcel Therapeutics's yearly revenue for 2023 was $1.38M, representing an increase of 268.00% compared to 2022. The company's yearly revenue for 2022 was $375K, representing an increase of 100.00% compared to 2021. BTAI's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.

What is BioXcel Therapeutics’s quarterly revenue?

BioXcel Therapeutics's quarterly revenue for Q2 2024 was $1.1M, a 89.69% increase from the previous quarter (Q1 2024), and a 141.58% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $582K, a 54.79% increase from the previous quarter (Q4 2023), and a 182.52% increase year-over-year (Q1 2023). BTAI's quarterly revenue for Q4 2023 was $376K, a 10.26% increase from the previous quarter (Q3 2023), and a 57.98% increase year-over-year (Q4 2022).

What is BioXcel Therapeutics’s revenue growth rate?

BioXcel Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.